| abstract |
The invention relates to medicine and can be used to quantify fibronectin in plasma. The goal is to increase the sensitivity, accuracy of the method and its simplification. Specific antifibrinonectin antibodies, erythrocytic diagnostics, and fibronectin content are determined in pre-adsorbed plasma samples. Erythrocytic diagnosticum is prepared from formalized erythrocytes in the presence of tannic acid. Sensitin is fibronectin isolated from human or horse blood,. In comparison with the prototype, sensitivity is provided (more than 70-120 times), the accuracy of the method and its simplification is achieved. o (l |